In the global pharmaceutical industry, there were 479 M&A deals announced in Q2 2023, worth a total value of $51bn, according to GlobalData’s Deals Database. The $10.8bn acquisition of prometheus biosciences by merck was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity decreased by 30% in Q2 2023 compared with the previous quarter’s total of $72.5bn and rose by 77% as compared to Q2 2022. Related deal volume increased by 18% in Q2 2023 versus the previous quarter and was 151% higher than in Q2 2022.
Notably, healthcare-related deals accounted for a 26% share of the global pharmaceutical industry’s M&A activity in Q2 2023, up 6% over the previous quarter.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Centerview Partners; Stifel Financial; Bank of America with 14, 8, 7 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Kirkland & Ellis; Cooley; Gibson, Dunn & Crutcher with 17, 14, 13 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.